Author(s):
Rose, Angela M.C. ; Nicolay, Nathalie ; Sandonis Martín, Virginia ; Mazagatos, Clara ; Petrović, Goranka ; Niessen, F Annabel ; Machado, Ausenda ; Launay, Odile ; Denayer, Sarah ; Seyler, Lucie ; Baruch, Joaquin ; Burgui, Cristina ; Loghin, Isabela I. ; Domegan, Lisa ; Vaikutytė, Roberta ; Husa, Petr ; Panagiotakopoulos, George ; Aouali, Nassera ; Dürrwald, Ralf ; Howard, Jennifer ; Pozo, Francisco ; Sastre-Palou, Bartolomé ; Nonković, Diana ; Knol, Mirjam J. ; Kislaya, Irina ; Luong Nguyen, Liem binh ; Bossuyt, Nathalie ; Demuyser, Thomas ; Džiugytė, Aušra ; Martínez-Baz, Iván ; Popescu, Corneliu ; Duffy, Róisín ; Kuliešė, Monika ; Součková, Lenka ; Michelaki, Stella ; Simon, Marc ; Reiche, Janine ; Otero-Barrós, María Teresa ; Lovrić Makarić, Zvjezdana ; Bruijning-Verhagen, Patricia C.J.L. ; Gómez, Verónica ; Lesieur, Zineb ; Barbezange, Cyril ; Van Nedervelde, Els ; Borg, Maria-Louise ; Castilla, Jesús ; Lazar, Mihaela ; O’Donnell, Joan ; Jonikaitė, Indrė ; Demlová, Regina ; Amerali, Marina ; Wirtz, Gil ; Tolksdorf, Kristin ; Valenciano, Marta ; Bacci, Sabrina ; Kissling, Esther ; I-MOVE-COVID-19 Hospital Study Team ; VEBIS Hospital Study Team
Date: 2023
Persistent ID: http://hdl.handle.net/10400.18/9106
Origin: Repositório Científico do Instituto Nacional de Saúde
Subject(s): COVID-19; SARS-CoV-2; Alpha; Delta; Vaccine Effectiveness; Hospitalisation; Europe; Vacina; Efetividade; IMOVE-COVID19; Cuidados de Saúde
Description
Introduction: Two large multicentre European hospital networks have estimated vaccine effectiveness (VE) against COVID-19 since 2021. Aim: We aimed to measure VE against PCR-confirmed SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients ≥ 20 years, combining data from these networks during Alpha (March–June)- and Delta (June–December)-dominant periods, 2021. Methods: Forty-six participating hospitals across 14 countries follow a similar generic protocol using the test-negative case–control design. We defined complete primary series vaccination (PSV) as two doses of a two-dose or one of a single-dose vaccine ≥ 14 days before onset. Results: We included 1,087 cases (538 controls) and 1,669 cases (1,442 controls) in the Alpha- and Delta-dominant periods, respectively. During the Alpha period, VE against hospitalisation with SARS-CoV2 for complete Comirnaty PSV was 85% (95% CI: 69–92) overall and 75% (95% CI: 42–90) in those aged ≥ 80 years. During the Delta period, among SARI patients ≥ 20 years with symptom onset ≥ 150 days from last PSV dose, VE for complete Comirnaty PSV was 54% (95% CI: 18–74). Among those receiving Comirnaty PSV and mRNA booster (any product) ≥ 150 days after last PSV dose, VE was 91% (95% CI: 57–98). In time-since-vaccination analysis, complete all-product PSV VE was > 90% in those with their last dose < 90 days before onset; ≥ 70% in those 90–179 days before onset. Conclusions: Our results from this EU multi-country hospital setting showed that VE for complete PSV alone was higher in the Alpha- than the Delta-dominant period, and addition of a first booster dose during the latter period increased VE to over 90%.
